2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to
guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with …

Aims To investigate in-hospital and long-term prognosis in T2DM patients presenting with
acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents …

Aims Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes
in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in …

BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with
type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF …

The purpose of this manuscript is to review the effects of sodium-glucose cotransport protein
2 inhibitors (SGLT2is) in patients with chronic kidney disease according to basic …

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor developed, has been shown to
reduce cardiovascular events in patients with type 2 diabetes and established …

Patients with AMI and hyperglycemia upon hospital admission exhibited poorer prognosis
compared with those without hyperglycemia. It is unknown whether SGLT2 inhibitors can …

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely used in cardiology and are
effective in treating acute coronary syndrome (ACS). Their effects on unstable plaque in …

Background Pharmacological post-MI treatment is routinely initiated at intensive/cardiac
care units. However, solid evidence for an early start of these therapies is only available for …